Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal transduction and targeted therapy, 2022, 7(1): 198. doi:10.1038/s41392-022-01042-7. [3] Hennrich U, Eder M. [177Lu] Lu-PSMA-617 (PluvictoTM): The First FDA-approved radiotherapeutical for treatment ...
[5]Gafita A, Rauscher I, Weber M, et al. Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study[J]. J Nucl Med, 2022, 63: 1651-1658. [6]Scher HI, Morris MJ, S...
参考来源：Novartis Pharma AG；Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer；March 23, 2022 16:19 ET 注：本文旨在介绍医药健康研究，不作任何用药依据，具体用药指引，请咨询主治医师。
原文出处:Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer 免责声明:本文仅作信息交流,文中的观点不代表中肽生化立场,亦不代表中肽生化支持或反对文中观点。本文也不构成投资建议,也不是研究治...
[1]Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl J Med, 2013, 369: 213-223. [2]Ahmadzadehfar H, Azgomi K, Hauser S, et al....
[2]Ng TSC,et al.(2021)IncorporatingPSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment:aMultidisciplinary Perspective.FrontOncol.doi:10.3389/fonc.2021.722277 [3]Czerwińska, M.et al.(2020).TargetedRadionuclide Therapy of Prostate Cancer-From Basic Research to ClinicalPerspectives.Molecul...
transmembrane glycoprotein expressed in prostate epithelial cells. compared with non-diseased prostate tissues, the expression of psma in prostate cancer was increased by 100-1 000 times. in recent years, psma has been attracted much...
[7].R.L. Tauber, et al. Treatment efficacy and safety of 177Lu-PSMA radioligand therapy in octogenarians with metastatic castration-resistant prostate cancer. 2022 ESMO. Abstract 1414P. [8].Hofman MS, Emmett L, Sandhu S, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with...
参考来源:Novartis Pharma AG;Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer;March 23, 2022 16:19 ET 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。
4. Liu J, Li Y, Yang D, et al. Current state of biomarkers for the diagnosis and assessment of treatment efficacy of prostate cancer. Discov Med. 2019 Jun;27(150):235-243. 5. Rauscher I, Maurer T, Steiger K, et al. Image of the Month: Multifocal 68Ga Prostate-Specific Membrane ...